Imatinib Basics

Imatinib, the active ingredient in Imatinib Basics, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Basics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib targets specific tyrosine‑kinase driven cancers and is employed in several approved indications. - Chronic myeloid leukemia: provides targeted inhibition of BCR‑ABL, improving hematologic and cytogenetic response. - Gastrointestinal stromal tumor: blocks c‑KIT signaling, reducing tumor growth and recurrence. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: offers a molecularly directed therapy that enhances remission rates.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet, or periorbital area. - Fatigue: persistent tiredness not relieved by rest. - Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or jaundice indicating liver injury. - Cardiac failure: signs of reduced heart function such as dyspnea. - Severe bleeding: gastrointestinal or intracranial hemorrhage requiring urgent care.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly. - Blood count monitoring: perform complete blood counts weekly for the first month, then periodically. - Liver function assessment: check ALT/AST levels before treatment and during therapy. - Cardiac evaluation: obtain baseline ECG in patients with known heart disease. - Hypersensitivity avoidance: discontinue if severe rash or anaphylaxis occurs. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several concomitant medications, requiring dose adjustments or close observation.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce therapeutic exposure. - Proton pump inhibitors: can lower absorption, potentially diminishing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR more frequently due to altered anticoagulant effect. - Digoxin: assess serum levels as imatinib may affect renal clearance.